Tolerability of Using a Post-Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation

Completed · Not applicable

Conditions studied: Skin Disorders

In brief

The purpose of this study is to compare the tolerability of the application of a combination of a serum containing human bone marrow stem cell derived growth factor (SCR Complex) and cytokines and a botanical lipid-based occlusive (Bio Cel) immediately following fractional radiofrequency treatment using the Venus Viva versus standard of care.

Key facts

Study ID

NCT02896569

Run by

Venus Concept

People needed

49

Starts

2016-08-01

Expected to finish

2017-02-27

Last updated by the study team

2020-11-03

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Undergoing a dermatological procedure requiring ablation and resurfacing of the facial skin utilizing the Venus Viva™ SR system.
• Women of child-bearing age are required to be using a reliable method of birth control prior to enrollment and throughout their participation in the study.
• Able to tolerate the treatment as determined by a test spot application(s).

You may not qualify if…

• Superficial metal or other implants in the treatment area
• Tattoos, permanent makeup, scars or piercings in the treatment area.
• Any active condition in the treatment area, such as sores, psoriasis, eczema and rash.
• Any surgical procedure in the treatment area within the last three months or before complete healing.
• Receiving therapies or medication that may interfere with the study treatment.

Where it is running

• Dr. George Taylor — Newport Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.